nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—pleura—esophageal cancer	0.221	0.55	CbGeAlD
Vidarabine—ADORA2A—NGF-independant TRKA activation—ADCYAP1—esophageal cancer	0.0517	0.136	CbGpPWpGaD
Vidarabine—ADORA2A—Activation of TRKA receptors—ADCYAP1—esophageal cancer	0.0447	0.118	CbGpPWpGaD
Vidarabine—DPP4—exocrine gland—esophageal cancer	0.0334	0.0832	CbGeAlD
Vidarabine—Apprehension—Cisplatin—esophageal cancer	0.0179	0.0878	CcSEcCtD
Vidarabine—Ear discomfort—Capecitabine—esophageal cancer	0.0154	0.0756	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—KRT14—esophageal cancer	0.015	0.0395	CbGpPWpGaD
Vidarabine—ADK—bronchus—esophageal cancer	0.0148	0.0368	CbGeAlD
Vidarabine—DPP4—epithelium—esophageal cancer	0.0145	0.0362	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—esophageal cancer	0.0145	0.036	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—esophageal cancer	0.014	0.0349	CbGeAlD
Vidarabine—ADA—digestive system—esophageal cancer	0.014	0.0347	CbGeAlD
Vidarabine—ADK—trachea—esophageal cancer	0.0133	0.033	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—esophageal cancer	0.0122	0.0322	CbGpPWpGaD
Vidarabine—ADA—lung—esophageal cancer	0.0117	0.029	CbGeAlD
Vidarabine—DPP4—digestive system—esophageal cancer	0.0111	0.0275	CbGeAlD
Vidarabine—ADK—Nucleotide metabolism—TYMP—esophageal cancer	0.0105	0.0276	CbGpPWpGaD
Vidarabine—ADK—lung—esophageal cancer	0.00953	0.0237	CbGeAlD
Vidarabine—ADA—C-MYB transcription factor network—CA1—esophageal cancer	0.00943	0.0248	CbGpPWpGaD
Vidarabine—DPP4—lung—esophageal cancer	0.00924	0.023	CbGeAlD
Vidarabine—DPP4—Peptide hormone metabolism—SLC30A7—esophageal cancer	0.00913	0.0241	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—BBC3—esophageal cancer	0.00907	0.0239	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—WWOX—esophageal cancer	0.00906	0.0239	CbGpPWpGaD
Vidarabine—Coronary artery disease—Cisplatin—esophageal cancer	0.00867	0.0426	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—SFN—esophageal cancer	0.00834	0.022	CbGpPWpGaD
Vidarabine—ADA—lymph node—esophageal cancer	0.00798	0.0198	CbGeAlD
Vidarabine—ADA—Nucleotide metabolism—TYMP—esophageal cancer	0.00713	0.0188	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—BBC3—esophageal cancer	0.00669	0.0176	CbGpPWpGaD
Vidarabine—ADK—lymph node—esophageal cancer	0.00652	0.0162	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—esophageal cancer	0.00642	0.0169	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—MMP14—esophageal cancer	0.00641	0.0169	CbGpPWpGaD
Vidarabine—DPP4—lymph node—esophageal cancer	0.00632	0.0157	CbGeAlD
Vidarabine—Sinus tachycardia—Capecitabine—esophageal cancer	0.00627	0.0308	CcSEcCtD
Vidarabine—Taste metallic—Methotrexate—esophageal cancer	0.00591	0.029	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—SFN—esophageal cancer	0.00551	0.0145	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—GHRL—esophageal cancer	0.00487	0.0128	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—CRTC1—esophageal cancer	0.00469	0.0124	CbGpPWpGaD
Vidarabine—Adenosine monophosphate—PDE4D—esophageal cancer	0.00468	0.313	CrCbGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—ABL1—esophageal cancer	0.00454	0.012	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—BAX—esophageal cancer	0.00416	0.011	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—ADCYAP1—esophageal cancer	0.00396	0.0105	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ABL1—esophageal cancer	0.00392	0.262	CrCbGaD
Vidarabine—Tenofovir—ABCC2—esophageal cancer	0.00365	0.244	CrCbGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—esophageal cancer	0.00363	0.00956	CbGpPWpGaD
Vidarabine—Torsade de pointes—Capecitabine—esophageal cancer	0.0036	0.0177	CcSEcCtD
Vidarabine—Pain—Carboplatin—esophageal cancer	0.00356	0.0175	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—ABL1—esophageal cancer	0.00335	0.00883	CbGpPWpGaD
Vidarabine—Ventricular fibrillation—Capecitabine—esophageal cancer	0.0033	0.0162	CcSEcCtD
Vidarabine—Tingling sensation—Capecitabine—esophageal cancer	0.00314	0.0154	CcSEcCtD
Vidarabine—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00314	0.0154	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—BAX—esophageal cancer	0.00307	0.00809	CbGpPWpGaD
Vidarabine—Extrasystoles—Capecitabine—esophageal cancer	0.003	0.0147	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—esophageal cancer	0.00288	0.00759	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—KDR—esophageal cancer	0.00286	0.00755	CbGpPWpGaD
Vidarabine—Chest discomfort—Capecitabine—esophageal cancer	0.00286	0.014	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.0028	0.0137	CcSEcCtD
Vidarabine—Nasal congestion—Cisplatin—esophageal cancer	0.00273	0.0134	CcSEcCtD
Vidarabine—Burning sensation—Methotrexate—esophageal cancer	0.00271	0.0133	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—CRTC1—esophageal cancer	0.00269	0.0071	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ADCYAP1—esophageal cancer	0.00264	0.00696	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—esophageal cancer	0.00258	0.00679	CbGpPWpGaD
Vidarabine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00254	0.0125	CcSEcCtD
Vidarabine—Blood pressure increased—Capecitabine—esophageal cancer	0.00253	0.0124	CcSEcCtD
Vidarabine—Injection site reaction—Capecitabine—esophageal cancer	0.00251	0.0123	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—CREBBP—esophageal cancer	0.00245	0.00645	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—PDE4D—esophageal cancer	0.00234	0.00616	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—GNG7—esophageal cancer	0.00222	0.00586	CbGpPWpGaD
Vidarabine—Apnoea—Methotrexate—esophageal cancer	0.00222	0.0109	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—RB1—esophageal cancer	0.00216	0.0057	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—esophageal cancer	0.00211	0.00555	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CREBBP—esophageal cancer	0.00207	0.00544	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00206	0.0101	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—GHRL—esophageal cancer	0.00204	0.00538	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ADCYAP1—esophageal cancer	0.00203	0.00536	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—esophageal cancer	0.002	0.00528	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ABCC2—esophageal cancer	0.00197	0.132	CrCbGaD
Vidarabine—Atrial fibrillation—Capecitabine—esophageal cancer	0.00194	0.0095	CcSEcCtD
Vidarabine—Respiratory failure—Methotrexate—esophageal cancer	0.00192	0.0094	CcSEcCtD
Vidarabine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00189	0.00928	CcSEcCtD
Vidarabine—Myocardial infarction—Cisplatin—esophageal cancer	0.00188	0.00923	CcSEcCtD
Vidarabine—Cardiac failure—Capecitabine—esophageal cancer	0.00188	0.00923	CcSEcCtD
Vidarabine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00187	0.00919	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.00181	0.00477	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—XBP1—esophageal cancer	0.0018	0.00474	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—BCL2—esophageal cancer	0.00178	0.00469	CbGpPWpGaD
Vidarabine—Bradycardia—Cisplatin—esophageal cancer	0.00175	0.0086	CcSEcCtD
Vidarabine—Cardiac arrest—Capecitabine—esophageal cancer	0.00174	0.00856	CcSEcCtD
Vidarabine—Mood swings—Capecitabine—esophageal cancer	0.00174	0.00853	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—SLC30A7—esophageal cancer	0.00172	0.00454	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—PTGS2—esophageal cancer	0.00169	0.00446	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—EP300—esophageal cancer	0.00167	0.00439	CbGpPWpGaD
Vidarabine—Tinnitus—Cisplatin—esophageal cancer	0.0016	0.00788	CcSEcCtD
Vidarabine—Flushing—Cisplatin—esophageal cancer	0.0016	0.00784	CcSEcCtD
Vidarabine—Cardiac disorder—Cisplatin—esophageal cancer	0.0016	0.00784	CcSEcCtD
Vidarabine—ADK—Metabolism—SLC52A3—esophageal cancer	0.00157	0.00414	CbGpPWpGaD
Vidarabine—ADK—Metabolism—BLVRB—esophageal cancer	0.00157	0.00414	CbGpPWpGaD
Vidarabine—Bronchospasm—Capecitabine—esophageal cancer	0.00156	0.00765	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—CDKN1A—esophageal cancer	0.00155	0.00409	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—ST6GAL1—esophageal cancer	0.00155	0.00409	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00155	0.00762	CcSEcCtD
Vidarabine—Arrhythmia—Cisplatin—esophageal cancer	0.00154	0.00755	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CCND1—esophageal cancer	0.00153	0.00403	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00152	0.00746	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1A—esophageal cancer	0.00148	0.0039	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—EP300—esophageal cancer	0.00148	0.00389	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00144	0.00379	CbGpPWpGaD
Vidarabine—Vision blurred—Cisplatin—esophageal cancer	0.00141	0.00693	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—EP300—esophageal cancer	0.00141	0.00371	CbGpPWpGaD
Vidarabine—Tremor—Cisplatin—esophageal cancer	0.0014	0.00689	CcSEcCtD
Vidarabine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00139	0.00684	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00139	0.00684	CcSEcCtD
Vidarabine—Myocardial infarction—Capecitabine—esophageal cancer	0.00139	0.0068	CcSEcCtD
Vidarabine—ADK—Metabolism—CA1—esophageal cancer	0.00134	0.00352	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC10A2—esophageal cancer	0.00134	0.00352	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKAP13—esophageal cancer	0.00131	0.00345	CbGpPWpGaD
Vidarabine—Convulsion—Cisplatin—esophageal cancer	0.0013	0.00637	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—esophageal cancer	0.00129	0.00635	CcSEcCtD
Vidarabine—Bradycardia—Capecitabine—esophageal cancer	0.00129	0.00634	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—MYC—esophageal cancer	0.00129	0.00339	CbGpPWpGaD
Vidarabine—Anxiety—Cisplatin—esophageal cancer	0.00127	0.00624	CcSEcCtD
Vidarabine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00126	0.0062	CcSEcCtD
Vidarabine—Discomfort—Cisplatin—esophageal cancer	0.00126	0.00619	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—esophageal cancer	0.00123	0.00323	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00122	0.006	CcSEcCtD
Vidarabine—ADK—Metabolism—CA2—esophageal cancer	0.00122	0.00322	CbGpPWpGaD
Vidarabine—Tachycardia—Cisplatin—esophageal cancer	0.00119	0.00586	CcSEcCtD
Vidarabine—Tinnitus—Capecitabine—esophageal cancer	0.00118	0.00581	CcSEcCtD
Vidarabine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00118	0.0058	CcSEcCtD
Vidarabine—Cardiac disorder—Capecitabine—esophageal cancer	0.00118	0.00578	CcSEcCtD
Vidarabine—Flushing—Capecitabine—esophageal cancer	0.00118	0.00578	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—GHRL—esophageal cancer	0.00117	0.00309	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—NOS2—esophageal cancer	0.00114	0.00302	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Capecitabine—esophageal cancer	0.00114	0.00561	CcSEcCtD
Vidarabine—Hypotension—Cisplatin—esophageal cancer	0.00114	0.00561	CcSEcCtD
Vidarabine—ADK—Metabolism—ADH7—esophageal cancer	0.00114	0.003	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PLCE1—esophageal cancer	0.00114	0.003	CbGpPWpGaD
Vidarabine—Arrhythmia—Capecitabine—esophageal cancer	0.00113	0.00556	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00113	0.00555	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00111	0.00547	CcSEcCtD
Vidarabine—Paraesthesia—Cisplatin—esophageal cancer	0.0011	0.00539	CcSEcCtD
Vidarabine—Dyspnoea—Cisplatin—esophageal cancer	0.00109	0.00535	CcSEcCtD
Vidarabine—Dysgeusia—Capecitabine—esophageal cancer	0.00108	0.00531	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—ACTB—esophageal cancer	0.00107	0.00282	CbGpPWpGaD
Vidarabine—ADA—Metabolism—BLVRB—esophageal cancer	0.00107	0.00282	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC52A3—esophageal cancer	0.00107	0.00282	CbGpPWpGaD
Vidarabine—Back pain—Capecitabine—esophageal cancer	0.00107	0.00524	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—esophageal cancer	0.00105	0.00517	CcSEcCtD
Vidarabine—Pain—Cisplatin—esophageal cancer	0.00105	0.00513	CcSEcCtD
Vidarabine—Vision blurred—Capecitabine—esophageal cancer	0.00104	0.00511	CcSEcCtD
Vidarabine—Tremor—Capecitabine—esophageal cancer	0.00103	0.00508	CcSEcCtD
Vidarabine—Sweating—Methotrexate—esophageal cancer	0.00101	0.00495	CcSEcCtD
Vidarabine—ADK—Metabolism—ADH1B—esophageal cancer	0.000997	0.00263	CbGpPWpGaD
Vidarabine—Syncope—Capecitabine—esophageal cancer	0.00099	0.00486	CcSEcCtD
Vidarabine—Palpitations—Capecitabine—esophageal cancer	0.000976	0.00479	CcSEcCtD
Vidarabine—Loss of consciousness—Capecitabine—esophageal cancer	0.000971	0.00477	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—HSPA5—esophageal cancer	0.000966	0.00255	CbGpPWpGaD
Vidarabine—Cough—Capecitabine—esophageal cancer	0.000964	0.00473	CcSEcCtD
Vidarabine—Hypertension—Capecitabine—esophageal cancer	0.000954	0.00468	CcSEcCtD
Vidarabine—ADK—Metabolism—TYMP—esophageal cancer	0.000953	0.00251	CbGpPWpGaD
Vidarabine—Chest pain—Capecitabine—esophageal cancer	0.00094	0.00462	CcSEcCtD
Vidarabine—Anxiety—Capecitabine—esophageal cancer	0.000937	0.0046	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—CALR—esophageal cancer	0.000936	0.00247	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000934	0.00246	CbGpPWpGaD
Vidarabine—Discomfort—Capecitabine—esophageal cancer	0.000929	0.00456	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP26A1—esophageal cancer	0.000927	0.00244	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—GHRL—esophageal cancer	0.00092	0.00243	CbGpPWpGaD
Vidarabine—Dry mouth—Capecitabine—esophageal cancer	0.00092	0.00451	CcSEcCtD
Vidarabine—ADA—Metabolism—CA1—esophageal cancer	0.000909	0.0024	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC10A2—esophageal cancer	0.000909	0.0024	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—FBXW7—esophageal cancer	0.000905	0.00239	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALOX15—esophageal cancer	0.000903	0.00238	CbGpPWpGaD
Vidarabine—Hypersensitivity—Cisplatin—esophageal cancer	0.000901	0.00442	CcSEcCtD
Vidarabine—Shock—Capecitabine—esophageal cancer	0.000887	0.00435	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—esophageal cancer	0.000881	0.00432	CcSEcCtD
Vidarabine—Tachycardia—Capecitabine—esophageal cancer	0.00088	0.00432	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—esophageal cancer	0.000877	0.00431	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—esophageal cancer	0.000877	0.0043	CcSEcCtD
Vidarabine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000871	0.00428	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000868	0.00229	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTO1—esophageal cancer	0.000861	0.00227	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TPI1—esophageal cancer	0.000861	0.00227	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000851	0.00418	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000844	0.00223	CbGpPWpGaD
Vidarabine—Hypotension—Capecitabine—esophageal cancer	0.000842	0.00414	CcSEcCtD
Vidarabine—ADA—Metabolism—CA2—esophageal cancer	0.000831	0.00219	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALDOB—esophageal cancer	0.000826	0.00218	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000823	0.00217	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000821	0.00403	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000813	0.00214	CbGpPWpGaD
Vidarabine—Paraesthesia—Capecitabine—esophageal cancer	0.000809	0.00397	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—GNG7—esophageal cancer	0.000807	0.00213	CbGpPWpGaD
Vidarabine—Dysgeusia—Methotrexate—esophageal cancer	0.000805	0.00395	CcSEcCtD
Vidarabine—Dyspnoea—Capecitabine—esophageal cancer	0.000804	0.00395	CcSEcCtD
Vidarabine—Back pain—Methotrexate—esophageal cancer	0.000795	0.0039	CcSEcCtD
Vidarabine—ADK—Metabolism—GAPDH—esophageal cancer	0.000795	0.0021	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CRABP1—esophageal cancer	0.000788	0.00208	CbGpPWpGaD
Vidarabine—Vomiting—Cisplatin—esophageal cancer	0.000777	0.00382	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—esophageal cancer	0.000775	0.0038	CcSEcCtD
Vidarabine—ADA—Metabolism—PLCE1—esophageal cancer	0.000773	0.00204	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ADH7—esophageal cancer	0.000773	0.00204	CbGpPWpGaD
Vidarabine—Rash—Cisplatin—esophageal cancer	0.000771	0.00379	CcSEcCtD
Vidarabine—Pain—Capecitabine—esophageal cancer	0.000771	0.00378	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—esophageal cancer	0.00077	0.00378	CcSEcCtD
Vidarabine—ADK—Metabolism—GNG7—esophageal cancer	0.000749	0.00198	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000739	0.00195	CbGpPWpGaD
Vidarabine—Nausea—Cisplatin—esophageal cancer	0.000726	0.00357	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCB1—esophageal cancer	0.000725	0.0485	CrCbGaD
Vidarabine—Cough—Methotrexate—esophageal cancer	0.000717	0.00352	CcSEcCtD
Vidarabine—Urticaria—Capecitabine—esophageal cancer	0.000716	0.00352	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—esophageal cancer	0.000712	0.0035	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL2—esophageal cancer	0.000711	0.00187	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALDH2—esophageal cancer	0.000702	0.00185	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—EP300—esophageal cancer	0.0007	0.00185	CbGpPWpGaD
Vidarabine—Chest pain—Methotrexate—esophageal cancer	0.0007	0.00344	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—esophageal cancer	0.000692	0.0034	CcSEcCtD
Vidarabine—ADA—Metabolism—ADH1B—esophageal cancer	0.000677	0.00179	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GDI2—esophageal cancer	0.000677	0.00179	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000671	0.00329	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTT1—esophageal cancer	0.000668	0.00176	CbGpPWpGaD
Vidarabine—Hypersensitivity—Capecitabine—esophageal cancer	0.000664	0.00326	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—ANXA1—esophageal cancer	0.000661	0.00174	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP2A6—esophageal cancer	0.00066	0.00174	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—NOS2—esophageal cancer	0.000657	0.00173	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000649	0.00318	CcSEcCtD
Vidarabine—ADA—Metabolism—TYMP—esophageal cancer	0.000647	0.00171	CbGpPWpGaD
Vidarabine—Asthenia—Capecitabine—esophageal cancer	0.000647	0.00318	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—SST—esophageal cancer	0.000643	0.00169	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP26A1—esophageal cancer	0.00063	0.00166	CbGpPWpGaD
Vidarabine—Hypotension—Methotrexate—esophageal cancer	0.000627	0.00308	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—GHRL—esophageal cancer	0.000627	0.00165	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS1—esophageal cancer	0.000626	0.00165	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ENO1—esophageal cancer	0.000626	0.00165	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PSME2—esophageal cancer	0.000617	0.00163	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PSME1—esophageal cancer	0.000617	0.00163	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALOX15—esophageal cancer	0.000614	0.00162	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000611	0.003	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—esophageal cancer	0.000603	0.00296	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—esophageal cancer	0.000598	0.00294	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—esophageal cancer	0.000597	0.00293	CcSEcCtD
Vidarabine—Dizziness—Capecitabine—esophageal cancer	0.000596	0.00293	CcSEcCtD
Vidarabine—ADA—Metabolism—GSTO1—esophageal cancer	0.000586	0.00154	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TPI1—esophageal cancer	0.000586	0.00154	CbGpPWpGaD
Vidarabine—Pain—Methotrexate—esophageal cancer	0.000574	0.00282	CcSEcCtD
Vidarabine—Vomiting—Capecitabine—esophageal cancer	0.000573	0.00281	CcSEcCtD
Vidarabine—Rash—Capecitabine—esophageal cancer	0.000568	0.00279	CcSEcCtD
Vidarabine—Dermatitis—Capecitabine—esophageal cancer	0.000568	0.00279	CcSEcCtD
Vidarabine—Headache—Capecitabine—esophageal cancer	0.000565	0.00277	CcSEcCtD
Vidarabine—ADA—Metabolism—ALDOB—esophageal cancer	0.000561	0.00148	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GAPDH—esophageal cancer	0.00054	0.00142	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CRABP1—esophageal cancer	0.000536	0.00141	CbGpPWpGaD
Vidarabine—Nausea—Capecitabine—esophageal cancer	0.000535	0.00263	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—esophageal cancer	0.000533	0.00262	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP1B1—esophageal cancer	0.000532	0.0014	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000524	0.00138	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GNG7—esophageal cancer	0.000509	0.00134	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TP53—esophageal cancer	0.000501	0.00132	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP19A1—esophageal cancer	0.0005	0.00132	CbGpPWpGaD
Vidarabine—Hypersensitivity—Methotrexate—esophageal cancer	0.000494	0.00243	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—KMT2D—esophageal cancer	0.00049	0.00129	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—esophageal cancer	0.000485	0.00128	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—esophageal cancer	0.000481	0.00236	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000479	0.00126	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALDH2—esophageal cancer	0.000477	0.00126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKAP13—esophageal cancer	0.000476	0.00125	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HMOX1—esophageal cancer	0.000457	0.0012	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GNG7—esophageal cancer	0.000456	0.0012	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTT1—esophageal cancer	0.000454	0.0012	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2A6—esophageal cancer	0.000449	0.00118	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—esophageal cancer	0.000444	0.00218	CcSEcCtD
Vidarabine—ADK—Metabolism—ABCB1—esophageal cancer	0.000438	0.00116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000436	0.00115	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PDE4D—esophageal cancer	0.000435	0.00115	CbGpPWpGaD
Vidarabine—Vomiting—Methotrexate—esophageal cancer	0.000427	0.00209	CcSEcCtD
Vidarabine—ADA—Metabolism—ENO1—esophageal cancer	0.000425	0.00112	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS1—esophageal cancer	0.000425	0.00112	CbGpPWpGaD
Vidarabine—Rash—Methotrexate—esophageal cancer	0.000423	0.00208	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—esophageal cancer	0.000423	0.00208	CcSEcCtD
Vidarabine—Headache—Methotrexate—esophageal cancer	0.00042	0.00206	CcSEcCtD
Vidarabine—ADA—Metabolism—PSME2—esophageal cancer	0.000419	0.00111	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSME1—esophageal cancer	0.000419	0.00111	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—esophageal cancer	0.000414	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GNG7—esophageal cancer	0.000414	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—esophageal cancer	0.000402	0.00106	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000402	0.00106	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—WWOX—esophageal cancer	0.000399	0.00105	CbGpPWpGaD
Vidarabine—Nausea—Methotrexate—esophageal cancer	0.000399	0.00196	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—FKBP1A—esophageal cancer	0.00038	0.001	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000374	0.000985	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—esophageal cancer	0.000373	0.000983	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—WIF1—esophageal cancer	0.000371	0.000978	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL2—esophageal cancer	0.000365	0.000962	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—SST—esophageal cancer	0.000363	0.000958	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1B1—esophageal cancer	0.000362	0.000954	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GHRL—esophageal cancer	0.000354	0.000933	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000342	0.000903	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP19A1—esophageal cancer	0.00034	0.000897	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ANXA1—esophageal cancer	0.000339	0.000894	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—esophageal cancer	0.000336	0.000886	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—SST—esophageal cancer	0.00033	0.00087	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GHRL—esophageal cancer	0.000322	0.000848	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PFN1—esophageal cancer	0.00032	0.000844	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—esophageal cancer	0.000319	0.00084	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HMOX1—esophageal cancer	0.00031	0.000818	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—esophageal cancer	0.000298	0.000785	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CREBBP—esophageal cancer	0.000293	0.000772	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	0.000292	0.000769	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ELMO1—esophageal cancer	0.000288	0.000758	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—esophageal cancer	0.000288	0.000758	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKAP13—esophageal cancer	0.000281	0.000741	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NOS3—esophageal cancer	0.000262	0.000691	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00026	0.000684	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—esophageal cancer	0.000258	0.000681	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDE4D—esophageal cancer	0.000257	0.000678	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNG7—esophageal cancer	0.000245	0.000645	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—esophageal cancer	0.00024	0.000632	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—XIAP—esophageal cancer	0.000229	0.000604	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—esophageal cancer	0.000224	0.000591	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNA1—esophageal cancer	0.000217	0.000571	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL2—esophageal cancer	0.000216	0.000568	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSME1—esophageal cancer	0.000201	0.000531	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSME2—esophageal cancer	0.000201	0.000531	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ANXA1—esophageal cancer	0.0002	0.000528	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—esophageal cancer	0.000199	0.000526	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CREBBP—esophageal cancer	0.000199	0.000525	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SST—esophageal cancer	0.000195	0.000514	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GHRL—esophageal cancer	0.00019	0.000501	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH3—esophageal cancer	0.00019	0.000501	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FBXW7—esophageal cancer	0.000187	0.000493	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NOS3—esophageal cancer	0.000178	0.00047	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH2—esophageal cancer	0.00017	0.000449	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—esophageal cancer	0.000163	0.00043	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFBR2—esophageal cancer	0.000151	0.000398	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—esophageal cancer	0.000148	0.000389	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMAD4—esophageal cancer	0.000143	0.000377	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—esophageal cancer	0.000136	0.000357	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIF1A—esophageal cancer	0.000117	0.000309	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KDR—esophageal cancer	0.000112	0.000295	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH1—esophageal cancer	0.000105	0.000278	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—esophageal cancer	0.0001	0.000264	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CREBBP—esophageal cancer	9.56e-05	0.000252	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—esophageal cancer	9.4e-05	0.000248	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	8.98e-05	0.000237	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOS3—esophageal cancer	8.56e-05	0.000226	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—esophageal cancer	8.15e-05	0.000215	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—esophageal cancer	8.01e-05	0.000211	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—esophageal cancer	7.07e-05	0.000186	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—esophageal cancer	6.84e-05	0.00018	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—esophageal cancer	6.51e-05	0.000172	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—esophageal cancer	5.67e-05	0.00015	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—esophageal cancer	5.55e-05	0.000146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—esophageal cancer	4.82e-05	0.000127	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—esophageal cancer	4.66e-05	0.000123	CbGpPWpGaD
